Kyorin Pharmaceutical Co., Ltd. and KAKEN PHARMACEUTICAL CO., LTD. signed an agreement regarding a marketing cooperation on Mirol (L-bunolol) Eye Drop 0.5%, an agent for the treatment of glaucoma and ocular hypertension. Kyorin obtained a license of the agent from Allergan, Inc. (U.S.A.) and got a sales and manufacturing approval from Japanese Health Authority as of July 3, 2000. Under this agreement, Kyorin consigned the product for sale in Japan to KAKEN.
In the process of restructuring the operation, Kyorin has intended to put emphasis on three marketing areas of Respiratory, Otorhinology and Urology. The consignment of Mirol makes it possible for Kyorin to gain more benefit, and to concentrate on the three areas. KAKEN is able to strengthen its product-lines in ophthalmic area by the consignment. Therefore, Kyorin and KAKEN reached an agreement on a marketing cooperation of Mirol. Kyorin supplies the finished-products to KAKEN.
Mirol indicates good intraocular pressure lowering activity with once daily administration, and its good efficacy and safety for glaucoma and ocular hypertension have been confirmed in the clinical studies. L-bunolol eye drop has been approved among 72 countries in the world since Allergan launched in the U.S. in 1986. Kyorin and KAKEN expect that Mirol will be widely used based on its excellent usefulness in Japan as well as in many other countries.
The features of Mirol are as follows: